[go: up one dir, main page]

WO2010044016A1 - Nouvelles utilisations pour l’esréboxétine et la réboxétine racémique - Google Patents

Nouvelles utilisations pour l’esréboxétine et la réboxétine racémique Download PDF

Info

Publication number
WO2010044016A1
WO2010044016A1 PCT/IB2009/054396 IB2009054396W WO2010044016A1 WO 2010044016 A1 WO2010044016 A1 WO 2010044016A1 IB 2009054396 W IB2009054396 W IB 2009054396W WO 2010044016 A1 WO2010044016 A1 WO 2010044016A1
Authority
WO
WIPO (PCT)
Prior art keywords
esreboxetine
patients
cognitive
pharmaceutically acceptable
fibromyalgia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/054396
Other languages
English (en)
Inventor
Amanda Jayne Ellis
Roderick Walter John Junor
Malcolm John Stoker
Laurence John Whelan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of WO2010044016A1 publication Critical patent/WO2010044016A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the invention relates to a number of novel uses for norepinephrine reuptake inhibitors, particularly esreboxetine and racemic reboxetine.
  • this invention relates to a norepinephrine reuptake inhibitor for use to improve cognitive function, and more particularly to a norepinephrine reuptake inhibitor for use to improve cognitive function in patients with fibromyalgia.
  • Fibromyalgia is a chronic condition characterised by wide spread muscle and joint pain; profound fatigue and sleep disturbance.
  • the American College of Rheumatology published criteria for the diagnosis of fibromyalgia as a history of widespread pain and pain in 1 1 of 18 pre-defined tender points (Wolfe et al. Arthritis Rheum 1995, 38(1 ), pp19-28).
  • the etiology of the disease remains unclear.
  • individuals diagnosed with fibromyalgia often suffer from comorbid conditions including depressive disorders, bipolar disorders, and anxiety disorders as well as other pain syndromes. These further complicate the treatment strategy.
  • the only marketed pharmacological treatment for fibromyalgia is pregabalin (LyricaTM, Pfizer Inc), although others are in development.
  • fibro fog Patients suffering from several different diseases, including Alzheimer's disease, major depressive disorder and schizophrenia, are known to experience concomitant or comorbid cognitive dysfunction or impairment. Reports have indicated that, in at least some cases, the cognitive dysfunction or impairment may be associated with malfunction of noradrenergic functioning (Friedman et al, Biol Psychiatry, 1999, 46, pp1243-1252). Recent findings have also reported that some fibromyalgia patients, in addition to the core symptoms of the disease, suffer from comorbid cognitive dysfunction or impairment (Glass, J. Clin. Psychiatry 2008, 69 (suppl 2), pp20-24). This has become commonly known as "fibro fog”.
  • the cognitive dysfunction of fibromyalgia sufferers can negatively impact their ability to function in everyday life, especially in the work place.
  • working memory is critical for accurate performance in demanding cognitive situations and it underlies successful performance in many other cognitive tasks.
  • a deficit in working memory ability has repercussive effects on other aspects of cognition, so that a small deficit in working memory can have a large impact.
  • Episodic memory or remembering recently presented information or events is an important aspect of everyday cognitive function and disruption seriously impacts one's ability to perform in the workplace.
  • deficits in verbal fluency impact a patient's ability to think quickly and come up with the right word for a given situation - again problematic in work place situations which require thinking on our feet.
  • fibromyalgia sufferers have been shown to have attention difficulties and in particular find it difficult to pay attention to things which are of importance while ignoring distracting items. These results are consistent with the reduced ability in working memory function because attention tests require people to store information for a short period and also process distracting information.
  • Anecdotally some fibromyalgia patients find the cognitive impairment more troubling than the other symptoms such as pain. Indeed certain sub- populations of fibromyalgia patients for whom cognitive dysfunction or impairment presents a particular concern may benefit from therapies able to target these symptoms specifically. As such there is a need to improve the cognitive function of patients with fibromyalgia, and particularly those who experience difficulties due to cognitive dysfunction or impairment.
  • Chronic fatigue syndrome is a debilitating disorder characterised by profound tiredness or fatigue (Schluederberg et al, Ann Intern Med 1992, 117, pp325- 331 ). Patients with chronic fatigue syndrome may become exhausted with only light physical exertion, and most often function at a level of activity substantially lower than their capacity before the onset of illness. In addition to the key defining characteristic of fatigue, patients with chronic fatigue syndrome generally report various non-specific symptoms including weakness, muscle aches and pains, excessive sleep, malaise, fever, sore throat, tender lymph nodes, insomnia and depression.
  • Schizophrenia is a psychotic disorder characterised by abnormalities in perception or expression of reality. Schizophrenia is usually described in terms of positive and negative symptoms. The positive symptoms include delusions, auditory hallucinations and thought disorder. The negative symptoms are so named because they are considered to be the loss or absence of normal traits including cognitive functioning. There is also a need to develop effective therapies to improve cognitive function of patients with schizophrenia.
  • United States Patent US 4229449 discloses racemic reboxetine, a 50:50 mixture of the two enantiomers of (2RS,3RS)-2-[ ⁇ -(2-ethoxyphenoxy)benzyl] morpholine
  • Racemic reboxetine is commercially sold under the trade names of EDRONAXTM, PROLIFTTM, VESTRATM, and NOREBOXTM for the treatment of depression.
  • racemic reboxetine and esreboxetine have also been disclosed in the art (WO 01/01973), including the use of racemic reboxetine and esreboxetine for the treatment of fibromyalgia and other somatoform disorders, chronic fatigue syndrome and psychotic disorders including schizophrenia.
  • Racemic reboxetine has been generally associated with cognitive functioning in some prior art documents. For example Kerr et al (Br J Clin Pharmacol, 1996, 42, pp239-241 ) have reported a study assessing whether or not racemic reboxetine affects the cognitive and psychomotor skills necessary for optimum function in everyday life. The results demonstrated that racemic reboxetine at doses of 4mg or less does not disrupt cognitive function. In another example Ferguson et al (Int Clinical Psychopharmacology 2003, vol 18 pp 9-14) have reported a study comparing racemic reboxetine with paroxetine on the effect of cognitive functioning in depressed patients.
  • prior art document WO 01/01973 discloses the use of both racemic reboxetine and esreboxetine to treat attention deficit disorders due to general medical conditions and prior art document WO 2006/000903 discloses the use of racemic reboxetine and esreboxetine as a mental performance enhancer.
  • norepinephrine reuptake inhibitors in particular esreboxetine and racemic reboxetine and more particularly esreboxetine, can be usefully used to improve cognitive function in patients with fibromyalgia.
  • these advantageous effects are as a result of the interaction of the norepinephrine reuptake inhibitor with the noradrenergic system which may in turn enhance cognitive processing. It is thought that this occurs because the central adrenergic system is closely associated with areas of the brain, in particular the prefrontal cortex, which may be associated with cognitive deficits.
  • norepinephrine reuptake inhibitors in particular esreboxetine and racemic reboxetine and more particularly esreboxetine, can be usefully used to improve cognitive function in patients with chronic fatigue syndrome for similar reasons.
  • norepinephrine reuptake inhibitors in particular esreboxetine and racemic reboxetine and more particularly esreboxetine, can be usefully used to improve cognitive function in patients with schizophrenia for similar reasons.
  • this invention relates to a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof, to improve cognitive function in patients with fibromyalgia.
  • this invention relates to a method of improving cognitive function in patients with fibromyalgia comprising administering to the patient in need of such improvement a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof.
  • this invention relates to the use of a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to improve cognitive function in patients with fibromyalgia.
  • this invention relates to a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof, to improve cognitive function in patients with chronic fatigue syndrome.
  • this invention relates to a method of improving cognitive function in patients with chronic fatigue syndrome comprising administering to the patient in need of such improvement a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof.
  • this invention relates to the use of a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to improve cognitive function in patients with chronic fatigue syndrome.
  • this invention relates to a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof, to improve cognitive function in patients with schizophrenia.
  • this invention relates to a method of improving cognitive function in patients with schizophrenia comprising administering to the patient in need of such improvement a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof.
  • this invention relates to the use of a norepinephrine reuptake inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to improve cognitive function in patients with schizophrenia.
  • the present invention relates to methods to improve cognitive function using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine.
  • a norepinephrine reuptake inhibitor preferably esreboxetine or racemic reboxetine, more preferably esreboxetine.
  • to improve includes for example demonstrating a clinically determined improvement from baseline using established methodology compared to placebo, in at least one objective cognitive test.
  • to improve also includes for example demonstrating a clinically determined improvement from baseline using established methodology compared to placebo, in at least one subjective cognitive test.
  • To improve should also be taken to include demonstrating a clinically determined improvement from baseline using established methodology compared to placebo, in at least one cognitive domain as assessed using one or more objective or subjective cognitive tests either alone or in combination.
  • Clinically suitable objective and subjective tests for measuring cognitive function are well known in the art. The exact test, or combination of tests, most suitable to demonstrate any particular improvement will depend upon the specific objective(s) of a given study and can be readily determined by one skilled in the art on a case by case basis.
  • cognitive function shall be taken to mean a person's ability to concentrate, remember things, make decisions / solve problems and think.
  • Cognitive function is well known to be divided into several different cognitive domains. Such domains include, but are not limited to, attention, memory, working memory, executive function, impaired information processing speed and efficiency, verbal fluency, impairments in memory, learning, memory capacity, long term memory, mental alertness, free recall, generalised dysregulation of the attention system, vocabulary deficits including verbal knowledge and verbal fluency and the like.
  • norepinephrine reuptake inhibitor shall be taken to mean those compounds that selectively inhibit the reuptake of norepinephrine, in particular those compounds that inhibit the reuptake of norepinephrine to a greater extent than they inhibit the reuptake of serotonin.
  • the norepinephrine reuptake inhibitor has a pharmacological selectivity of serotonin (K,) / norepinephrine (K,) of at least about 5, more preferably of at least about 25, even more preferably of at least about 100 and still more preferably of at least about 1000.
  • norepinephrine reuptake inhibitors include, but are not limited to, atomoxetine, racemic reboxetine and esreboxetine.
  • Preferred examples or norepinephrine reuptake inhibitors include racemic reboxetine and esreboxetine. The most preferred norepinephrine reuptake inhibitor is esreboxetine.
  • the term "esreboxetine”, sometimes known as (S, S)- reboxetine, shall be taken to mean the single enantiomer (2S,3S)-2-[ ⁇ -(2- ethoxyphenoxy)benzyl]morpholine and which is substantially free of its (R, R) enantiomer. In a preferred embodiment this shall mean that the (S, S)- reboxetine comprises at least 90 wt% of (S, S)-reboxetine and less than 10 wt% of (R, R)-reboxetine.
  • the (S, S)- reboxetine comprises at least 95 wt% of (S, S)-reboxetine and less than 5 wt% of (R, R)-reboxetine. In an even more preferred embodiment (S, S)- reboxetine comprises at least 97 wt% of (S, S)-reboxetine and less than 3 wt% of (R, R)-reboxetine. In a yet further preferred embodiment (S, S)- reboxetine comprises at least 99 wt% of (S, S)-reboxetine and less than 1 wt% of (R, R)-reboxetine.
  • racemic reboxetine shall be taken to mean a mixture of the two enantiomers of (2RS,3RS)-2-[ ⁇ -(2- ethoxyphenoxy)benzyl]morpholine. Usually such a mixture will comprise equal amounts of each of the two enantiomers but mixtures which are enriched in one enantiomer or another will still be considered to fall into the scope of the present invention.
  • SNRI dual serotonin and norepinephrine reuptake inhibitor
  • the dual serotonin and norepinephrine reuptake inhibitor has a pharmacological selectivity of serotonin (K,) / norepinephrine (K,) of about 1 , more preferably of less than about 1.
  • Methods for measuring selectivity ratios are well known in the art and include, for example, those described in International Patent Application WO 00/01973.
  • Examples of dual serotonin and norepinephrine reuptake inhibitor include, but are not limited to, venlafaxine, milnacipram, desipramine and duloxetine.
  • the present invention relates to methods to improve cognitive function in patients with fibromyalgia using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine.
  • a norepinephrine reuptake inhibitor preferably esreboxetine or racemic reboxetine, more preferably esreboxetine.
  • To improve cognitive function in patients with fibromyalgia includes, but is not limited to, demonstrating an improvement in at least one of the cognitive domains of attention, memory, working memory, executive function, impairments in memory, learning, memory capacity, long term memory, mental alertness, free recall, generalised dysregulation of the attention system, and vocabulary deficits including verbal knowledge and verbal fluency.
  • patients with fibromyalgia shall be taken to mean patients who have been diagnosed to be suffering from fibromyalgia according to the American College of Rheumatology criteria (Wolfe et al, 1990). This includes in particular those patients who experience comorbid or concomitant cognitive dysfunction or impairment which is associated with their fibromyalgia and are therefore in need of an improvement in their cognitive functioning. In particular this invention is particularly useful for those fibromyalgia patient sub-populations which may be identified for whom cognitive impairment or cognitive dysfunction is of greater concern.
  • the present invention relates to methods to improve cognitive function in patients with fibromyalgia using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine, where the improved cognitive domain is "attention".
  • a norepinephrine reuptake inhibitor preferably esreboxetine or racemic reboxetine, more preferably esreboxetine
  • the term "attention” shall be taken to mean the ability of a patient to selectively concentrate on one aspect of the environment while ignoring other things.
  • the present invention relates to methods to improve cognitive function in patients with fibromyalgia using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine, where the improved cognitive domain is "memory".
  • a norepinephrine reuptake inhibitor preferably esreboxetine or racemic reboxetine, more preferably esreboxetine
  • memory shall be taken to mean the ability of the patient to remember specific events or episodes.
  • the present invention relates to methods to improve cognitive function in patients with fibromyalgia using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine, where the improved cognitive domain is " working memory".
  • a norepinephrine reuptake inhibitor preferably esreboxetine or racemic reboxetine, more preferably esreboxetine
  • working memory shall be taken to mean the amount of mental power or online cognitive resource a person has available in any given situation.
  • the present invention relates to methods to improve cognitive function in patients with fibromyalgia using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine, where the improved cognitive is "executive function".
  • a norepinephrine reuptake inhibitor preferably esreboxetine or racemic reboxetine, more preferably esreboxetine
  • execution function shall be taken to mean the ability of the patient to plan, demonstrate cognitive flexibility and to select relevant sensory information.
  • the present invention also relates to methods to improve cognitive function in patients with chronic fatigue syndrome using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine.
  • Improvements of cognitive function in patients with chronic fatigue syndrome include, but are not limited to, improvements in at least one of the cognitive domains of attention, memory, working memory and executive function, impairment in memory, learning, memory capacity, impaired information processing speed and efficiency.
  • patients with chronic fatigue syndrome shall be taken to mean patients who have been diagnosed to be suffering from chronic fatigue syndrome according to one or both of the two widely used criteria for diagnosing chronic fatigue syndrome, namely that established by the "US Centers for Disease and Prevention” and that established in the “Oxford criteria” and both as set out in Reid et al (British Medical journal, 200, 320, pp292-296). This includes those patients who experience comorbid or concomitant cognitive dysfunction or impairment which is associated with their chronic fatigue syndrome and are therefore in need of an improvement in their cognitive functioning.
  • the present invention also relates to methods to improve cognitive function in patients with schizophrenia using a norepinephrine reuptake inhibitor, preferably esreboxetine or racemic reboxetine, more preferably esreboxetine.
  • Improvements of cognitive function in patients with schizophrenia include, but are not limited to, improvements in at least one of the cognitive domains of attention, memory, working memory and executive function.
  • patients with schizophrenia shall be taken to mean patients who have been diagnosed to be suffereing from schizophrenia according to one or both of the two widely used criteria for diagnosing schizophrenia, namely that set out by the American Psychiatric associate's diagnostic and statistical manual of mental disorders version DSM-IV-TR as set out in American Psychiatric Association (2000).
  • Esreboxetine and racemic reboxetine contain a basic group, and may therefore be converted to a pharmaceutically acceptable salt by reaction with an acid.
  • Suitable acid addition salts are formed from acids which form nontoxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate
  • a pharmaceutically acceptable salt of esreboxetine or racemic reboxetine may be readily prepared in a conventional manner by mixing together solutions of esreboxetine or racemic reboxetine and the desired acid, as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • the degree of ionisation in the salt may vary from completely ionised to almost non-ionised.
  • Esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
  • compositions suitable for the delivery of esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof, and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).
  • esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled lozenges), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays.
  • Formulations suitable for oral administration also include liquid formulations such as suspensions, solutions, syrups and elixirs.
  • Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents.
  • Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet, esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof, may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001 ).
  • the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form.
  • tablets generally contain a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate.
  • the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form.
  • Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
  • lactose monohydrate, spray-dried monohydrate, anhydrous and the like
  • mannitol xylitol
  • dextrose sucrose
  • sorbitol microcrystalline cellulose
  • starch dibasic calcium phosphate dihydrate
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
  • surface active agents such as sodium lauryl sulfate and polysorbate 80
  • glidants such as silicon dioxide and talc.
  • surface active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • Lubricants generally comprise from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet.
  • ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt- granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
  • Solid formulations for oral administration may be formulated to have immediate and / or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6, 106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma ef a/, Pharmaceutical Technology On-line, 25(2), 1-14 (2001 ). The use of chewing gum to achieve controlled release is described in WO 00/35298.
  • Esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof may also be administered parenterally, that is directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • a suitable vehicle such as sterile, pyrogen-free water.
  • the preparation of parenteral formulations under sterile conditions for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • solubility of esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof, used in the preparation of parenteral solutions may be increased by techniques which are commonly used in the art such as by the use of appropriate formulation techniques, such as the incorporation of solubility- enhancing agents.
  • Formulations for parenteral administration may be formulated to have immediate and / or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug- coated stents and PGLA microspheres.
  • Esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used.
  • Typical carriers for such formulations include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
  • Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955- 958 by Finnin and Morgan (October 1999).
  • Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. PowderjectTM, BiojectTM, etc.) injection.
  • Formulations for topical administration may be formulated to have immediate and / or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • Esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 ,1 ,1 ,2- tetrafluoroethane or 1 , 1, 1,2,3,3,3-heptafluoropropane.
  • a suitable propellant such as 1 ,1 ,1 ,2- tetrafluoroethane or 1 , 1, 1,2,3,3,3-heptafluor
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • the pressurised container, pump, spray, atomizer, or nebuliser typically contains a solution or suspension of esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof, comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or "puff".
  • Capsules made, for example, from gelatin or HPMC
  • blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof, a suitable powder base such as lactose or starch and a performance modifier such as /-leucine, mannitol, or magnesium stearate.
  • the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
  • Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
  • a suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 ⁇ g to 20mg of esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof, per actuation and the actuation volume may vary from 1 ⁇ l to 100 ⁇ l.
  • a typical formulation may comprise esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof, propylene glycol, sterile water, ethanol and sodium chloride.
  • Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
  • Suitable flavours such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
  • Formulations for inhaled/intranasal administration may be formulated to have immediate and / or modified release using, for example, poly(DL-lactic- coglycolic acid) (PGLA).
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • Esreboxetine or racemic reboxetine, or pharmaceutically acceptable salts thereof may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline.
  • Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes.
  • a polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride.
  • a preservative such as benzalkonium chloride.
  • Such formulations may also be delivered by iontophoresis.
  • Formulations for ocular/aural administration may be formulated to have immediate and / or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.
  • daily dose of the composition contains from about 0.1 to about 10 mg of esreboxetine or racemic reboxetine.
  • each dose of the composite contains about 0.5 to about 10 mg of the active ingredient, esreboxetine or racemic reboxetine.
  • This dosage form permits the full daily dosage of about 0.5 to about 10 mg to be administered in one or two doses. More preferably the dosage form permits the full daily dose to be administered in one dose.
  • Specific embodiments include oral doses which comprise 2mg, 4mg, 6mg, 8mg or 10mg of esreboxetine.
  • Alternative embodiments include oral doses which comprise 2mg, 4mg, 6mg, 8mg or 10mg of racemic reboxetine.
  • the norepinephrine reuptake inhibitor including esreboxetine or racemic reboxetine can be administered alone or in combination with one or more other drugs (or as any combination thereof).
  • other active compounds which can be usefully administered with esreboxetine or racemic reboxetine include, for example, anti-depressants, analgesics, muscle relaxants, anoretics, stimulants, anti-epileptic drugs, beta blockers, and sedative or hypnotics.
  • specific examples of such compounds include, but are not limited to, gabapentin, pregabalin, duloxetine, milnacipram, pramipexole, and combinations thereof.
  • administration in combination with another drug includes simultaneous administration in the same dosage forms, simultaneous administration in separate dosage forms and separate administration of the compounds.
  • the primary objective of this study is to evaluate if esreboxetine improves specific cognitive domains, namely attention, memory, working memory and executive function, in fibromyalgia patients using objective testing.
  • Another objective of this study is to evaluate if esreboxetine improves cognitive functioning in general in patients with fibromyalgia as assessed using certain subjective questionnaires.
  • test methods include:
  • Multifactorial memory questionnaire (MMQ) (Troyer and Rich, Journal of
  • the eight primary end points used to determine cognitive function will be analysed separately and no formal adjustment will be made for multiplicity.
  • To determine the effect of esreboxetine compared to placebo on cognitive function the change from baseline for each primary endpoint will be analysed using a mixed effect analysis of covariance including fixed terms for treatment, period and sequence and a random effect term for subject.
  • the baseline visit will be defined as the pre-dose assessment in each treatment period.
  • the treatment difference and corresponding 80% confidence interval will be presented. Descriptive statistics will also be used to summarise both the absolute and change from baseline for each endpoint by treatment group, timepoint and period. All analysis will be carried out on the full analysis set.
  • each sub-scale of the MASQ the daily pain diary and the pain visual analogue scale will be analysed and summarised as for the primary endpoints.
  • Each dimension of the MMQ will be summarised only at randomisation.
  • Each patient rating of cognition question will be summarised descriptively by frequency of each response to each question split by treatment group, timepoint and period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un inhibiteur de la recapture de la norépinéphrine, ou un sel pharmaceutiquement acceptable de celui-ci, de préférence l’esréboxétine ou la réboxétine racémique, idéalement l’esréboxétine, pour améliorer la fonction cognitive, notamment pour améliorer la fonction cognitive chez les patients souffrant de fibromyalgie. La présente invention concerne également des procédés de traitement de la fibromyalgie.
PCT/IB2009/054396 2008-10-17 2009-10-07 Nouvelles utilisations pour l’esréboxétine et la réboxétine racémique Ceased WO2010044016A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10628008P 2008-10-17 2008-10-17
US61/106,280 2008-10-17

Publications (1)

Publication Number Publication Date
WO2010044016A1 true WO2010044016A1 (fr) 2010-04-22

Family

ID=41382399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/054396 Ceased WO2010044016A1 (fr) 2008-10-17 2009-10-07 Nouvelles utilisations pour l’esréboxétine et la réboxétine racémique

Country Status (1)

Country Link
WO (1) WO2010044016A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106825A1 (fr) * 2016-12-06 2018-06-14 Tonix Pharmaceuticals Holding Corp. Sels et polymorphes de l'esreboxetine
US10699403B2 (en) 2014-01-06 2020-06-30 L.I.F.E. Corporation S.A. Systems and methods to automatically determine garment fit
US12447155B2 (en) 2018-10-15 2025-10-21 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076461A1 (fr) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combinaison de reboxetine et de citalopram
WO2004010998A1 (fr) * 2002-07-25 2004-02-05 Pharmacia Corporation Comprime a liberation prolongee comprenant de la reboxetine
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning
US20060128705A1 (en) * 1999-07-01 2006-06-15 Pharmacia & Upjohn Company Method of treating chronic fatigue syndrome
AU2007200599A1 (en) * 1999-07-01 2007-03-01 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128705A1 (en) * 1999-07-01 2006-06-15 Pharmacia & Upjohn Company Method of treating chronic fatigue syndrome
AU2007200599A1 (en) * 1999-07-01 2007-03-01 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
WO2002076461A1 (fr) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combinaison de reboxetine et de citalopram
WO2004010998A1 (fr) * 2002-07-25 2004-02-05 Pharmacia Corporation Comprime a liberation prolongee comprenant de la reboxetine
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10699403B2 (en) 2014-01-06 2020-06-30 L.I.F.E. Corporation S.A. Systems and methods to automatically determine garment fit
WO2018106825A1 (fr) * 2016-12-06 2018-06-14 Tonix Pharmaceuticals Holding Corp. Sels et polymorphes de l'esreboxetine
US12447155B2 (en) 2018-10-15 2025-10-21 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy

Similar Documents

Publication Publication Date Title
US20240100039A1 (en) Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
JP2021098743A (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
US20090036487A1 (en) Combinations
US20140343069A1 (en) Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20120046302A1 (en) Methods of treating cns disorders
CN119174751A (zh) 用于治疗焦虑相关病症的组合物和方法
US20180369211A1 (en) Methods and compositions for treating neurodegenerative disorders
WO2010044016A1 (fr) Nouvelles utilisations pour l’esréboxétine et la réboxétine racémique
US7247623B2 (en) Method of treating dry eye disease with non-drying antihistamines
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
US20240299375A1 (en) Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
US20100081719A1 (en) Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
US20220062265A1 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
US20080058318A1 (en) Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
US20230228740A1 (en) Method of using human spheroids for drug discovery
Patat et al. Effects of single and multiple doses of a new reversible MAO‐A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects
US20240350433A1 (en) Treatment compositions and methods
Roller et al. Disease state management: Depression and antidepressants
US20230381169A1 (en) Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist
JP2003221337A (ja) 酢酸アミド誘導体を有効成分とする痴呆症治療剤
Roller et al. Disease state management: Mood disorders: Part one: Depression and antidepressants
Zornig the beauty of~ relief.
US20070060617A1 (en) 2-Methoxy-5(5-trifluoromethyl-tetrazol-1-yl-benzyl)-2s-phenyl-piperdin-3s-yl)-amine for the treatment of social phobia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09740542

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09740542

Country of ref document: EP

Kind code of ref document: A1